Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $45 from $29 and keeps an Equal Weight rating on the shares. Recent data from Ionis’ (IONS) Phase 3 CORE/CORE2 studies of olezarsen in severe hypertriglyceridemia increases the firm’s conviction in the potential of Arrowhead’s plozasiran in SHTG, notes the analyst, who updated the firm’s model ahead of key SHASTA 3/4 data expected in Q3 of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals Advances Alzheimer’s Treatment with New Clinical Study
- Arrowhead Pharmaceuticals Advances Cholesterol Treatment with Phase 3 Study
- Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study
- Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia
- Arrowhead Pharmaceuticals Advances in SCA2 Treatment with ARO-ATXN2 Study